Nyrada Inc. (ASX: NYR): Shares Suddenly Return to Traders' Radar Following Sharp Price Movement
Nyrada (ASX: NYR) shares have seen sharp volatility as traders react to its Xolatryp clinical progress and Phase IIa plans. Despite strong preclinical results and early trial safety data, the stock remains speculative, driven by momentum trading, retail interest, and upcoming biotech milestones.
Nyrada (ASX: NYR) $14M Capital Raise: Fueling the Path to Global Pharma Partnerships
As Nyrada (ASX: NYR) raises $14 million to advance Xolatryp through Phase IIa trials, the funding extends its development runway and could accelerate clinical milestones, potentially positioning the company for future partnerships with global pharmaceutical companies.
Nanoveu (ASX: NVU): 16nm SoC Milestone and US Patent to Redefine Edge AI
While Nanoveu (ASX: NVU) has yet to release performance data from its 16nm ECS-DoT chip, receiving physical silicon from TSMC validates the design and moves the platform closer to benchmarking, partner evaluation, and potential commercialisation.
.webp&w=828&q=75)
Telix Pharmaceuticals (ASX: TLX): $1.65B ITM Deal Expands Its Radiopharmaceutical Footprint
Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion, with up to $700 million in contingent consideration, expanding Telix’s isotope supply capabilities and radiopharmaceutical platform.
DroneShield (ASX: DRO): Strong Growth, but Can Earnings Catch Up?
DroneShield (ASX: DRO) delivered record 1H26 revenue of $125.8M (+74%) and growing recurring software revenue, but margins fell to 60%, costs surged, and a $32.2M statutory loss raises questions on whether earnings can catch up to justify its share price.
